A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts

Neoplasia

Volumn 3, Issue 5, 2001, Pages 428-436

  Williams, Christopher S ^a   Hongmiao, Sheng ^a   Brockman, Jeffrey A ^a   Armandla, Radhika ^a   Shao, Jinyi ^a   Washington, M Kay ^a   Elkahloun, Abdel G ^a   Dubois, Raymond N ^a,b,c,d  

^a Department of Medicine ^*  (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer prevention; Cell cycle arrest; Colorectal cancer; COX 2; Prostaglandins

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; CYCLOOXYGENASE 2 INHIBITOR; PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE G2 PHASE; COLON CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; TREATMENT PLANNING; XENOGRAFT;

EID: 0034769855     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900177     Document Type: Article

References (28)

1. Sulindac suppresses tumorigenesis in the min mouse
2. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
3. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis
4. Colon cancer
5. G1 delay in intestinal epithelial cells overexpressing prostaglandin endoperoxide synthase-2
6. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
7. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
8. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
9. Meloxicam inhibits the growth of colorectal cancer cells
10. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway
11. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
12. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenase in chicken embryo fibroblasts
13. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis
14. Δ716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2)
15. Apoptosis primarily accounts for the growth-inhibitory properties sulindac metabolites and involves a mechanism that is independent cyclooxygenase inhibition, cell cycle arrest, and p53 induction
16. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent
17. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
18. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methyl-caffeate, and 6-phenylhexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention and promotion
19. NSAIDs, gastrointestinal injury and cytoprotection
20. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
21. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells
22. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis
23. Sulindac sulfide, an aspirin-like compound, inhibits causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells
24. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells
25. Senescent cells fail to express cdc2, cycA, and cycB in response to mitogen stimulation
26. Aspirin use and reduced risk of fatal colon cancer
27. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells
28. Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513, Arg and lle523 Val mutation